Outcomes of Coronary Artery Bypass Grafting in Israeli Jews and Arabs

Retrospective study of adult patients with multivessel disease undergoing isolated CABG in three centers between January 1st, 2009, and December 31st, 2023. The primary outcome was a composite of major adverse cardiac and cerebrovascular events (MACCE). Patients were grouped according to their ethnic origin, Arabs and Jews.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

CABG Ethnic Group

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

isolated CABG

Exclusion criteria

members of different HMO

Treatment and study plan

CABG

Procedure

All patients underwent isolated CABG and retrospectively followed to asses ethnic disparities

Primary outcomes

MACCE

Time frame: through study completion, a median of 78 months

Secondary outcomes

Mortality

Time frame: through study completion, a median of 78 months
MI

Time frame: through study completion, a median of 78 months
CVA

Time frame: through study completion, a median of 78 months
repeat revascularization

Time frame: through study completion, a median of 78 months
utilization of multi-arterial grafting

Time frame: through study completion, a median of 78 months

Sponsors and collaborators

Lead sponsor

Technion, Israel Institute of Technology

Other

Registry information

Important dates

Study start: 2009
Primary completion: 2023
Study completion: 2023
First posted: Jan 9, 2025
Registry last updated: Jan 9, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed